B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Agenus (AGEN – Research Report) today and set a price target of $8.00. The company's shares closed last Tuesday at $2.35, close to its 52-week low of $2.28. According to TipRanks.com, Mamtani 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -26.6% and a 23.8% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals, and Spectrum Pharmaceuticals. Currently, the analyst consensus on Agenus is a Moderate Buy with an average price target of $11.00.
https://www.tipranks.com/news/blurbs/b-riley-financial-thinks-agenus-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Agenus Charts.
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Agenus Charts.